In fact, increased soluble ST2 in serum of AD patients was reported [21]: IL-33 reduces β-amyloid levels and amyloid plaques and reverses synaptic plasticity impairment and memory deficit in a mouse model [21]. This evidence concerns the gene IL33 and Alzheimer disease.